Please find information on the IPO of Marinomed Biotech AG below.

Company: Marinomed Biotech AG
ISIN: ATMARINOMED6
Symbol: MARI
Trading Segment: Official Market
Market Segment: prime market
Category: no-par value bearer shares
Number of Shares (before IPO): 1,000,000 ordinary shares
Share Capital (before IPO): EUR 1,000,000.--
First Day of Trading: 1 February 2019
Offered Shares:
up to 260,000 shares
up to 40,000 shares (upsize option)
up to 45,000 shares (greenshoe)
Offering Period: scheduled from 24 January 2019 until 29 January 2019
Price Fixing: 29 January 2019
Price Range: EUR 75.-- to EUR 90.--
Offer Price: EUR 75,--
Issuing Volume: EUR 19.5 million excl. greenshoe
Sole Global Coordinators, Underwriter and Sole Bookrunners: Erste Group Bank AG
Manager: goetzpartners securities Limited
Management Board:
Andreas Grassauer
Eva Prieschl-Grassauer
Pascal Schmidt
Supervisory Board:
Simon Nebel
Ute Lassnig
Karl Lankmayr
Gernot Hofer
Brigitte Ederer
Shareholder Structure (before IPO):
Acropora Beteiligungs GmbH - 33.29%
Hermann Unger - 13.03%
Andreas Grassauer - 12.78%
Eva Prieschl-Grassauer - 12.78%
Invest Unternehmensbeteiligungs
Aktiengesellschaft - 10.29%
aws Mittelstandsfonds Beteiligungs
GmbH & Co KG - 10.00%
VETWIDI Forschungsholding GmbH - 3.96%
Pascal Schmidt - 2.00%
Helmut Baranyovszki - 0.87%
Martin Platzer - 0.50%
Angelika Bodenteich - 0.49%
Total 100%
Address:
Veterinärplatz 1
1210 Vienna
T +43 (0)1 250774460
Internet:
www.marinomed.com
Marinomed Biotech AG Logo

About Marinomed Biotech AG

(Profile provided by the company)

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners.

The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.

Disclaimer

This website contains forward-looking statements and forecasts based on assumptions and expectations current at the time of publication. These forward-looking statements involve risks and uncertainties, and therefore, actual developments or events may turn out to be completely different from those expressed or implied by such statements. Forward-looking statements should not be understood as a guarantee of future developments or events, nor should readers place undue reliance on such statements. Wiener Börse AG does not assume any liability whatsoever for the forward-looking statements or forecasts, and actual events may differ materially from those expressed in these forward-looking statements or forecasts. The forward-looking statements in this press release are based on assumptions and expectations current at the time of publication and will not be updated at a later time. None of the information or statements on this website may be construed as a solicitation to buy or a recommendation to invest by Wiener Börse AG and neither can such information or statements serve as a basis for investment decisions in any country or for any person.